deltatrials
Completed PHASE2 NCT00045734

Imatinib Mesylate in Treating Patients With Recurrent Meningioma

Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma

Sponsor: National Cancer Institute (NCI)

Conditions Adult Grade I Meningioma Adult Grade II Meningioma Adult Grade III Meningioma Adult Meningeal Hemangiopericytoma Adult Meningioma Recurrent Adult Brain Tumor
Interventions imatinib mesylate laboratory biomarker analysis pharmacological study
Updated 8 times since 2017 Last updated: May 2, 2017 Started: Feb 28, 2003 Primary completion: Dec 31, 2009 Completion: Dec 31, 2009

Listed as NCT00045734, this PHASE2 trial focuses on Adult Grade I Meningioma and Adult Grade II Meningioma and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 8 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshotCompleted~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotCompleted~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 19 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 3 earlier versions

  1. Jul 2017 — Jun 2018 [monthly]

    Completed PHASE2

  2. Feb 2017 — Jul 2017 [monthly]

    Completed PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Feb 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations